This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Psoriasis
  • /
  • Risankizumab: an anti-IL-23 antibody for the treat...

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis

Read time: 1 mins
Published:12th Nov 2018
Author: Haugh IM, Preston AK, Kivelevitch DN, Menter AM.
Availability: Free full text
Ref.:Drug Des Devel Ther. 2018 Nov 12;12:3879-3883.
Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis

Risankizumab, a fully human IgG monoclonal antibody inhibitor of IL-23, is a therapeutic agent currently in late stage development for use in the treatment of moderate-to-severe plaque psoriasis. It is a biologic agent similar to guselkumab and tildrakizumab which targets IL-23 specifically, and has been primarily developed for use in moderate-to-severe psoriasis. USA-based pharmaceutical company Abbvie submitted it for a Biologics License Application to the US Food and Drug Administration (FDA) in April 2018. Risankizumab is the result of a collaboration between the German company Boehringer Ingelheim and Abbvie, which together are leading the future development and commercialization of risankizumab globally. The results from Phase I to Phase III clinical trials of risankizumab show it is highly effective and its FDA-approval in 2018 is likely. In this article we provide an independent expert opinion on the efficacy and safety of risankizumab in psoriasis based on a full review of the literature.

Read abstract on library site    Access full article